abemaciclib
69 abstracts
Abstract
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.Org: Winship Cancer Institute of Emory University, IRCCS Ospedale San Raffaele, Sarah Cannon Research Institute/Tennessee Oncology, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University,
Abstract
Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Alliance Statistics and Data Management Center, Mayo Clinic Rochester,
Abstract
CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer.Org: Massachusetts General Hospital Cancer Center and Harvard Medical School, Institut Català d’Oncologia–Bellvitge Institute for Biomedical Research, Studienpraxis Urologie, Asan Medical Center, Hospital Universitario Gregorio Marañón,
Abstract
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).Org: Peter MacCallum Cancer Centre, Melbourne, Australia, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UT Southwestern Simmons Comprehensive Cancer Center, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University,
Abstract
Nationwide real-world practice pattern and clinical data of palbociclib in patients with HR(+), HER2(-) metastatic breast cancer (KCSG BR21-15).Org: Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Seoul, Seoul, South Korea, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Characterization of molecular response and progression in patients with metastatic HR+/HER2- breast cancer receiving endocrine therapy and CDK4/6 inhibitors using a high-sensitivity tumor-informed assay.Org: Division of Medical Oncology & Hematology,
Abstract
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study.Org: Memorial Sloan Kettering Cancer Center, University of Vermont Cancer Center, Université Libre de Bruxelles (ULB), Institut Jules Bordet, Université Libre de Bruxelles, Medical Oncology Department,
Abstract
Abemaciclib dose escalation to maintain intensity (ADE-MI).Org: University of Illinois Hospital & Health Sciences System, University of Illinois Chicago, University of Illinois at Chicago, University of Illinois Chicago College of Pharmacy,
Abstract
Innovation of the first-line strategy optimized as abemaciclib with endocrine therapy based on the ESR1 mutation of ctDNA for patients with HR-positive HER2-negative advanced metastatic breast cancer (JBCRG-M08; AMBER study).Org: Osaka University Hospital, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Nagoya University Hospital,
Abstract
Implementing geriatric assessment for dose optimization of CDK 4/6 inhibitors in older breast cancer patients (IMPORTANT trial): A pragmatic randomized-controlled trial.Org: Örebro University Hospital, Santo Stefano Hospital, General Hospital of Patras St. Andrews, Akershus University Hospital (Ahus), Papageorgiou General Hospital,
Abstract
ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.Org: Dana-Farber Cancer Institute/Harvard Medical School, Mayo Clinic, Department of Biostatistics & Data Science, The University of North Carolina at Chapel Hill, The University of Texas MD Anderson Cancer Center,
Abstract
pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2– locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant (adj) endocrine therapy (ET).Org: Winship Cancer Institute of Emory University, Dana-Farber Cancer Institute, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, University Hospital Erlangen, Hospital Alemán,
Abstract
A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer.Org: Memorial Sloan Kettering Cancer Center, Interventional Radiology Service,
Abstract
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).Org: University of California, San Francisco, Mayo Clinic, University of Chicago Medical Center, Chicago, IL, Winship Cancer Institute of Emory University, Hunstman Cancer Institute at the University of Utah,
Abstract
Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation.Org: Pangaea Oncology, Breast Oncology Institute, Sermonix Pharmaceuticals, Mayo Clinic, Medical Oncology,
Abstract
Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.Org: Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China, Breast Surgery, Jiangxi Cancer Hospital, Nanchang, China, Hunan Cancer Hospital, Changsha, China, Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China,
Abstract
Evaluating Ki67 and Oncotype DX Breast Recurrence Score during neoadjuvant treatment with letrozole/abemaciclib or chemotherapy in patients with highly proliferative HR+/HER2- breast cancer participating in the GEICAM CARABELA trial.Org: Spanish Breast Cancer Group, Málaga,
Abstract
Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study.Org: Sarah Cannon Research Institute/Tennessee Oncology, Asan Medical Center, Samsung Medical Center, Menarini Group, Hospital Universitario 12 de Octubre,
Abstract
Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.Org: Baylor University Medical Center, Texas Oncology, The US Oncology Network, International Breast Cancer Center (IBCC), Quironsalud Group,
Abstract
Symptom management through electronic patient-reported outcome (ePRO)-based intervention in patients with breast cancer treated with abemaciclib: Primary results from the LIBRA study, a phase II randomized controlled trial.Org: Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Keio University School of Medicine, Keio University School of Medicine General Surgery, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Department of Breast Medical Oncology, Japanese Foundation for Cancer Research,
Abstract
An exploratory study on prediction of risk for abemaciclib-induced interstitial lung disease or hepatotoxicity by specific human leukocyte antigen alleles.Org: Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan, Department of Breast Medical Oncology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, Tokyo, Japan, Department of Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan, Department of Breast Surgery, Kansai Rosai Hospital, Amagasaki, Japan,
Abstract
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.Org: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Northwestern Memorial Hospital, Chicago, IL, Chicago, IL, Il-Yang Pharmaceuticals, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+/HER2- aBC: Results of the multicenter, real-world, Italian study PALMARES-2.Org: IRCCS Policlinico S. Matteo, Dip Scienze Medico Chirurgiche Medicina, ICS Maugeri IRCCS, Ospedale di Mirano Dolo, ASST Fatebenefratelli Sacco,
Abstract
AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, University of Chicago Medicine, UCSF Helen Diller Family Comprehensive Cancer Center,
Abstract
Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: A systematic review and meta-analysis.Org: Services Institute of Medical Sciences,
Abstract
(CDK) 4/6 inhibitors: An effective treatment for homologous recombination deficient (HRD) luminal breast cancers (BC)?Org: UNEB,
Abstract
The association of hormone receptor expression level and clinical efficacy of CDK4/6 inhibitor in hormone receptor-positive, HER2-negative metastatic breast cancer.Org: Department of Clinical Oncology, Queen Elizabeth Hospital, Queen Elizabeth Hospital, Hong Kong Sanatorium & Hospital,
Abstract
Frequency of dose reductions of abemaciclib in metastatic and early-stage hormone positive, HER2 negative breast cancer.Org: Scripps Clinic/Green Hospital, La Jolla, CA,
Abstract
The association between age, toxicity and outcomes of abemaciclib treatment in HR+/HER2- metastatic breast cancer.Org: Faculty of Medicine, University of Ljubljana,
Abstract
The impact of vitamin D levels on the progression-free survival of women with hormone receptor-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors.Org: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,
Abstract
Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with abemaciclib, in endometrioid endometrial cancer (EEC): Results from the EMBER phase 1a/1b study.Org: Next Oncology Virginia and Virginia Cancer Specialists, Sir Charles Gairdner Hospital, Calvary Mater Hospital, University of Vermont Cancer Center, Stephenson Cancer Center,
Abstract
Cost-effectiveness of adjuvant abemaciclib and ribociclib in high-risk, hormone receptor–positive, early breast cancer in India.Org: Department of Medical Oncology, BRA-IRCH,
Abstract
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.Org: University of Chicago Medicine, University of Chicago, University of Chicago Medical Center, Chicago, IL,
Abstract
Efficacy and safety of dalpiciclib, fulvestrant, and pyrotinib in HR+ HER2-low advanced breast cancer following cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and aromatase inhibitors (AIs): A Bayesian optimal phase II trial.Org: First Hospital of China Medical University,
Abstract
Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University,
Abstract
Real-world comparison of the efficacy of three CDK4/6 inhibitors (CDK4/6i) in the first-line treatment of endocrine-sensitive advanced breast cancer (aBC): Single institution experience.Org: School of Medicine, University of Zagreb, Department of Pathology, University Hospital Center Zagreb, Department of Pathology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Center,
Abstract
Real-world treatment outcomes in patients with HR+ HER2- advanced breast cancer treated with CDK4/6 inhibitors and endocrine therapy.Org: Military Institute of Medicine-National Research Institute, Department of Oncology, National Taiwan University Hospital, Department of Clinical Oncology, Queen Elizabeth Hospital, Breast Unit, Lower Silesian Oncology Centre,
Abstract
Optimization of surgical management of the axilla since MonarchE trial.Org: Georges François Leclerc Comprehensive Cancer Care Centre, Centre Georges François Leclerc, Centre Georges Francois Leclerc,
Abstract
Cancer outcomes from a real-world cohort of patients eligible for adjuvant CDK4/6 inhibitors but without genomic risk for chemotherapy: A GBECAM multicenter retrospective study.Org: Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Hospital Moinhos de Vento, Sírio Libanês Hospital, Hospital Sírio-Libanês, A.C. Camargo Cancer Center,
Abstract
Identification of a predictive phosphoproteomic signature of response to atezolizumab and bevacizumab (AB) in patients with advanced hepatocellular carcinoma (aHCC).Org: Institute of Liver Studies, Kinomica Limited,
Abstract
Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).Org: Tennessee Oncology, PLLC, University General Hospital of Heraklion, Hospital de Cancer de Londrina, Baskent University Faculty of Medicine, Mater Adult Hospital Brisbane,
Abstract
Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).Org: The Netherlands Cancer Institute, Erasmus MC Cancer Institute, Netherlands Comprehensive Cancer Organisation (IKNL), Erasmus School of Health Policy & Management, Spaarne Gasthuis,
Abstract
Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2- metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update.Org: University of Texas MD Anderson Cancer Center, Cleveland Clinic Foundation, St. Joseph Heritage Health, Ohio State University Wexner Medical Center, Mayo Clinic,
Abstract
A single-arm, phase 2 clinical trial of abemaciclib in adult patients with recurrent grade 3 oligodendroglioma.Org: Hospital of the University of Pennsylvania, University of Pennsylvania,
Abstract
Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.Org: University of Toronto, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Centre Hospitalier Universitaire de Québec,
Abstract
Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer.Org: Yong Loo Lin School of Medicine, National University of Singapore (NUS), Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, National University Cancer Institute, Mediclinic City Hospital,
Abstract
Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.Org: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, Toronto, ON, Canada,
Abstract
TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer.Org: University of Texas MD Anderson Cancer Center, Sunnybrook Odette Cancer Centre, University of Toronto, The Ottawa Hospital and University of Ottawa, Washington University School of Medicine in St Louis,
Abstract
Utility of Ki67 in guiding adjuvant abemaciclib therapy for patients with hormone receptor (HR)-positive, early breast cancer (EBC).Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Morningside-West, Icahn School of Medicine, Tisch Cancer Institute,
Abstract
ORACLE-RIPA study: A phase II, randomized, open-label, parallel-group study comparing the immune modulation effect of neoadjuvant ribociclib, palbociclib, and abemaciclib in early ER+/HER2- breast cancer.Org: National Taiwan University Hospital Yunlin Branch, National Taiwan University Cancer Center/Hospital,
Abstract
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.Org: Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL, USA, Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA, Massachusetts General Hospital, Columbia University Irving Medical Center, New York, NY, USA, University of Virginia, Charlottesville, VA, USA,
Abstract
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.Org: Clinical Care Options, LLC, Reston, VA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer.Org: Memorial Sloan Kettering Cancer Center, START Midwest, Grand Rapids, MI, Valkyrie Clinical Trials, Inc, Stanford Hospital & Clinics, Virginia Cancer Specialists,
Abstract
Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital 12 de Octubre, Hospital Clínic de Barcelona, IDIBAPS, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), SOLTI Breast Cancer Cooperative Group,
Abstract
A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.Org: Memorial Sloan Kettering Cancer Center, University of Texas MD Anderson Cancer Center, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Abemaciclib in recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) harboring CDKN2A loss, and/or CCND1 and/or CDK6 amplification: A phase II multicenter trial.Org: Centre Léon Bérard, Centre de Lutte Contre le Cancer Antoine Lacassagne, GINECO-Centre Jean Perrin, Clermont-Ferrand, France, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Hôpital Saint-André,
Abstract
Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).Org: Hospital Infantil Universitario Niño Jesús, Vall d'Hebron Barcelona Hospital Campus, National Cancer Center Hospital East, Kashiwa, Japan, Fondazione Policlinico Universitario A. Gemelli IRCCS, Phoenix Children's Hospital,
Abstract
HER2-low expression as a prognostic factor in patients treated with CDK4/6 inhibitors: A retrospective analysis.Org: Virgen del Rocio Hospital, Institute of Biomedicine of Seville (IBiS), CSIC, Universidad de Sevilla, Andalusian - Roche Network Mixed Alliance in Precision Medical Oncology,
Abstract
A randomized, open-label, phase 2 study evaluating abemaciclib in combination with irinotecan and temozolomide in participants with relapsed or refractory Ewing sarcoma.Org: Eli Lilly and Company, Pediatric Oncology-Hematology Department, National Cancer Center Hospital East, Kashiwa, Japan, Hospital U i P La Fe, Peter MacCallum Cancer Centre, Melbourne, Australia,
Abstract
BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer (MBC): Results from a phase I study.Org: Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Shanghai, China, Gracell Biotechnologies, Ltd., Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The Third Hospital of Nanchang,
Abstract
Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C).Org: University of Minnesota Masonic Cancer Center, Minneapolis, MN, Riley Hospital for Children at Indiana University Health, The Warren Alpert Medical School of Brown University, David Geffen School of Medicine UCLA, Cohen Children's Medical Center,
Abstract
CDK4/6 inhibitors and cardiovascular toxicity: Real-world evidence.Org: National and Kapodistrian University of Athens, Alexandra University Hospital,
Abstract
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Washington University School of Medicine in St Louis, Mayo Clinic, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
Efficacy of abemaciclib versus tucidinostat after progression on palbociclib in patients with HR+/HER2− MBC: A multicenter retrospective cohort study.Org: Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center Gansu Hospital, The First Hospital of China Medical University, Shenyang, China, Department of Medical Oncology, Liaoning Cancer Hospital & Institute, The First Affiliated Hospital with Nanjing Medical University,
Abstract
Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia: ARORA Registry.Org: Walter and Eliza Hall Institute of Medical Research, Eastern Health, Royal North Shore Hospital, Sydney, Australia, St Vincent's Private Hospital, The Mater Hospital Sydney,
Abstract
A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1/2 ERK1/2, and NF1.Org: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Indiana University Simon Cancer Center and Roudebush VAMC, Department of Hematology/Oncology, IU Simon Comprehensive Cancer Center, Melvin and Bren Simon Cancer Center, Indianapolis, IN,
Abstract
Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity.Org: EHC, Morges, Switzerland, University Hospital 12 de Octubre, Institut Curie, Saint Cloud, France, Centre GF Leclercq,
Abstract
Clinical benefit of personalized treatment following high throughput sequencing in metastatic melanoma: A national retrospective study.Org: Dermatology and Skin Cancer Department, AP-HM Marseille, Dermatology Departement, Cochin Hospital, APHP,Université Paris Cité, Paris, France, CHU de Bordeaux, Cochin Hospital,